Antiviral Treatment in Older Chinese Patient with SARS-CoV-2 and Influenza A Virus Co-Infection: A Case Series
Wenjuan Yang,Bing Han,Bei Zheng,Ying Li,Tiefei Yao,Mei Han,Gonghua Li,Meiling Zhang
DOI: https://doi.org/10.2147/IDR.S418178
2023-07-22
Infection and Drug Resistance
Abstract:Wenjuan Yang, 1, 2 Bing Han, 1 Bei Zheng, 1 Ying Li, 1 Tiefei Yao, 3 Mei Han, 3 Gonghua Li, 1 Meiling Zhang 1 1 Department of Pharmacy, Tongde Hospital of ZheJiang Province, Hangzhou, Zhejiang, People's Republic of China; 2 Zhejiang Academy of Traditional Chinese Medicine, Hangzhou, Zhejiang, People's Republic of China; 3 Department of Geriatric Medicine, Tongde Hospital of ZheJiang Province, Hangzhou, Zhejiang, People's Republic of China Correspondence: Gonghua Li; Meiling Zhang, Department of Pharmacy, Tongde Hospital of ZheJiang Province, Hangzhou, Zhejiang, People's Republic of China, Tel +86-0571-89972239, Email ; Coronavirus disease 2019 (COVID-19) emergence in late 2019, and wide spread quickly in the world. In China, the COVID-19 epidemic situation entered a low level now. With the arrival of flu season, the number of patients with respiratory symptoms is increasing. We reported three cases of patients who co-infected with SARS-CoV-2 and influenza A virus (IAV), and they were all treated with nirmatrelvir-ritonavir (NMV/r) and baloxavir marboxil. Due to the overlapping clinical features between the two diseases, it is important to identified them and gave the antiviral therapy timely. Keywords: COVID-19, influenza, co-infection, baloxavir marboxil, nirmatrelvir-ritonavir Coronavirus disease 2019 (COVID-19), caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), first emerged in late 2019 and has spread rapidly across the globe. In China, COVID-19 emerged as a large-scale epidemic in February 2020 and entered a normalization stage for prevention and control in May 2020. 1,2 Most nonpharmaceutical interventions (NPIs) were canceled in 2022, except for indoor mask-wearing. 3 After three years of anti-epidemic efforts, COVID-19 public health control measures were downgraded in China in January 2023, and the epidemic situation reached a low level. 4 However, studies have speculated that the number of individuals susceptible to influenza infection increased after the easing of NPIs, which could lead to a large epidemic in many countries, including China. Additionally, the coexistence of COVID-19 and influenza in the upcoming season could pose a significant threat to the population, potentially altering the transmission patterns of the diseases and exacerbating the disease burden. 5,6 Recently, a study quantified the rebound of influenza activity in southern and northern China during the 2023–2024 and 2024–2025 epidemiological years and found that the epidemic would increase by 3.8 times and 3.0 times, respectively, in southern China and northern China when the NPIs were completely relaxed in the 2022–2023 period, and which would be more pronounced in southern China, partly due to the relatively low rebound of influenza activity in the 2021–2022 period. 7 Study illustrated that co-infection with influenza A virus (IAV) can enhance the infectivity of SARS-CoV-2. 8 As a result, physicians should be vigilant about the possibility of co-infection cases with particularly in vulnerable patients such as the elderly and immunosuppressed individuals, and prioritize early diagnosis and combined antiviral treatment. However, distinguishing between SARS-CoV-2 and IAV poses a challenge due to their similar clinical symptoms and mode of transmission. 9 Fever and cough are the most common clinical signs shared by both SARS-CoV-2 and IAV. However, runny nose is a prominent clinical finding in IAV cases but less common in COVID-19 patients. Moreover, COVID-19 patients tend to exhibit more abnormalities of the lower respiratory system on chest imaging compared to IAV cases. 10 Compared to IAV, COVID-19 patients commonly experience fatigue, headache, myalgia, and digestive tract symptoms as early signs of the disease. Furthermore, elevated C-reactive protein levels are more frequently observed in COVID-19 patients, and these patients tend to have higher levels of creatine kinase. 11 Currently, reverse transcription polymerase chain reaction (RT-PCR) remains the gold standard diagnostic method for detecting SARS-CoV-2 and IAV. 12 However, a recent study proposed using a multiplex quantitative RT-qPCR method to quickly diagnose co-infection in suspected patients. This method offers faster results and is more cost-effective than the conventional monoplex quantitative RT-qPCR-based method. 13 Furthermore, vaccination continues to play a crucial role in controlling the resurgence of the influenza epidemic. A study suggested that influenza vaccination rates should be increased to 53.8% in southern China and 33.8% in northern China to control the influenza epidemic and return -Abstract Truncated-
pharmacology & pharmacy,infectious diseases